Hanna Eriksson

Hanna Eriksson | Karolinska Institutet (ki.se)

Cutaneous melanoma is one of the deadliest forms of skin cancer. The survival
is heterogenous both between and within disease stages. Early detection and
surgical removal of the primary melanoma is still crucial for the prognosis.
Landmark genomic and immunologic studies have translated into approved
targeted treatments and immunotherapies for metastatic disease. Targeted
therapies achieve high but often transient therapy responses. Immunotherapies
can achieve durable responses in a subset of patients. Serious immune
associated toxicities are a major clinical challenge.
Our overall objective is therefore to optimally inform clinical
decision-making and improve the outcome from early disease to advanced
melanoma.
Hanna Eriksson's Group | Karolinska Institutet (ki.se) [1]

I am currently main-supervisor for PhD-students postodocs.
PhD course organizer for:
Clinical Oncology for Pre-Clinical Doctoral Students (#5505), Karolinska
Institutet.
Basic Course in Tumor Biology and Oncology (#3112), Karolinska Institutet.